Biography

Blaise Coleman is a forward-thinking, results-driven pharmaceutical executive and board member with deep financial expertise and a proven track record of leading successful transformations. As President, Chief Executive Officer, and Board Member at Endo—a diversified specialty pharmaceutical company—Mr. Coleman led a multiyear transformation plan. This included the execution of new targeted portfolio and capability growth investments, as well as significant operational improvements that resulted in more than $200 million in annual cost savings. To resolve extensive legacy legal matters, he executed a voluntary Chapter 11 restructuring, successfully resolving all legal and tax matters, significantly reducing debt, and positioning Endo for long-term sustainable value creation. Earlier at Endo, Mr. Coleman served as Executive Vice President & Chief Financial Officer and as Senior Vice President Global Finance Operations.

Prior to joining Endo, Mr. Coleman held finance leadership roles with AstraZeneca, including Chief Financial Officer, U.S. Diabetes Business. Earlier in his career, he served as the Business Development and Commercial Finance Leader at Centocor, a wholly-owned subsidiary of Johnson & Johnson.

​Mr. Coleman is a Certified Public Accountant and previously worked as a Manager in the Pharmaceutical Assurance Practice at PwC. He earned a Master of Business Administration at the Duke University Fuqua School of Business and a Bachelor of Science in Accounting at Widener University.